Patients achieving sustained deep remission, deep remission or sustained remission of rheumatoid arthritis are more likely than other responders to maintain remission or low disease activity after dose reduction or withdrawal of etanercept

Tanaka, Y, Smolen, JS, Jones, H et al. (3 more authors) (2019) Patients achieving sustained deep remission, deep remission or sustained remission of rheumatoid arthritis are more likely than other responders to maintain remission or low disease activity after dose reduction or withdrawal of etanercept. Arthritis Research and Therapy, 21. 164. ISSN 1478-6354

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © Pfizer Inc. 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Keywords: Rheumatoid arthritis; Anti-TNF; Etanercept; Remission; Dose reduction; Withdrawal; DAS28; ACR/EULAR Boolean; CDAI
Dates:
  • Published: 5 July 2019
  • Accepted: 5 June 2019
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Inflammatory Arthritis (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 07 Jun 2019 09:39
Last Modified: 17 Jul 2019 14:01
Status: Published
Publisher: BioMed Central
Identification Number: https://doi.org/10.1186/s13075-019-1937-4

Share / Export

Statistics